164
Views
0
CrossRef citations to date
0
Altmetric
Original Articles: Gynaecology

Screening for PIK3CA mutations among Saudi women with ovarian cancer

, , , , , , , , , , , & show all

References

  • Abe A, Minaguchi T, Ochi H, Onuki M, Okada S, Matsumoto K, et al. 2013. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Human Pathology 44:199–207.
  • Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, et al. 2009. PIK3CA alterations in Middle Eastern ovarian cancers. Molecular Cancer 8:51.
  • Ahmed HG, Al-Adhraei MA, Al-Thobhani AK. 2011. Correlations of Hormone Receptors (ER and PR), Her2/neu and p53 Expression in Breast Ductal Carcinoma among Yemeni Women. The Open Cancer Immunology Journal 4:1–9.
  • Berek JS, Kehoe ST, Kumar L, Friedlander M. 2018. FIGO Cancer Report 2018, Cancer of the ovary, fallopian tube and peritoneum. International Journal of Gynecology & Obstetrics 143:59–78.
  • Bozhanov SS, Angelova SG, Krasteva ME, Markov TL, Christova SL, Gavrilov IG, et al. 2010. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. Journal of Cancer Research and Clinical Oncology 136:1657–1669.
  • Campbell IG, Russell SE, Choong DYH, Montgomery KG, Ciavarella ML, Hooi CSF, et al. 2004. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Research 64:7678–7681.
  • Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. 2001. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology 82:532–537.
  • Cho KR, Shih Ie M. 2009. Ovarian cancer. Annual Review of Pathology 4:287–313.
  • De Marco C, Rinaldo N, Bruni P, Malzoni C, Zullo F, Fabiani F, et al. 2013. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. PLoS One. 8:e55362.
  • Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. 2019. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer 144:1941–1953.
  • GLOBOCAN 2018. Saudi Arabia-Global cancer observatory. [accessed on 12 December 2019]. Available at: https://gco.iarc.fr/today/data/factsheets/populations/682-saudi-arabia-fact-sheets.pdf
  • Karakas B, Bachman KE, Park BH. 2006. Mutation of the PIK3CA oncogene in human cancers. British Journal of Cancer 94:455–459.
  • Kurman RJ, Shih I-M. 2010. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. The American Journal of Surgical Pathology 34:433–443.
  • Mabuchi S, Kuroda H, Takahashi R, Sasano T. 2015. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynaecologic Oncology 290(6):1067–1078.
  • Madsen RR, Vanhaesebroeck B, Semple RK. 2018. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends in Molecular Medicine 24:856–870.
  • Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. 2019. Ovarian cancer in the world: epidemiology and risk factors. International Journal of Women's Health 11:287–299. Published 2019 Apr 30.
  • Ness RB, Cottreau C. 1999. Possible role of ovarian epithelial inflammation in ovarian cancer. Journal of the National Cancer Institute 91:1459–1467.
  • Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, et al. 2013. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecologic Oncology 130:554–559.
  • Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. 2005. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Research 65:2554–2559.
  • Samuels Y, Waldman T. 2010. Oncogenic mutations of PIK3CA in human cancers. Current Topics in Microbiology and Immunology 347:21–41.
  • Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. 1999. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 21:99–102.
  • Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. 2001. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. The American Journal of Pathology 159:2249–2256.
  • Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, et al. 2007. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Human Pathology 38:607–613.
  • Woenckhaus J, Steger K, Sturm K, Münstedt K, Franke FE, Fenic I. 2007. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Archiv: An International Journal of Pathology 450:387–395.
  • Younes N, Zayed H. 2019. Genetic epidemiology of ovarian cancer in the 22 Arab countries: A systematic review. Gene 684:154–164.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.